Open in app

First mRNA vaccine data from India will be investigated by NTAGI

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:
(Image Courtesy: - Business Standard)

Data concerning the first Covid mRNA vaccine developed in India will likely be discussed shortly by the Covid working group of the National Technical Advisory Group on Immunization (NTAGI). The Drugs Controller General of India recently approved the first domestically produced mRNA Covid-19 vaccine for use in patients 18 years of age and above. The vaccine was created at Pune's Gennova Biopharmaceuticals (DCGI). Discussion of Biological E's Corbevax booster dosage for Covishield and Covaxin recipients is also reportedly on the agenda for the NTAGI Covid working group. According to reports, the Subject Expert Committee (SEC) of India's drug regulator was pleased with the information provided by the business located in Pune during its meeting last week. In April, Gennova Biopharmaceuticals provided the information. They responded in May after being pushed for further details. The pharmaceutical business said that their monthly production goal of 4-5 million doses can be swiftly quadrupled once they receive approval from the government. The Central Drug Laboratory in Kasauli has authorised and distributed 7 million doses for the corporation. In addition to India, Gennova wants to provide access to low- and middle-income nations everywhere to stop pandemics from spreading. Gennova Biopharmaceuticals Ltd.'s mRNA vaccine will be offered for sale under the trade name GEMCOVAC-19. The business and the government are also talking about the vaccine's price. Because GEMCOVAC-19 is a thermostable vaccine and can be kept between 2 and 8 C, it is ideal for use in India and other poor countries because it can be readily transported to the most remote areas. In contrast, Pfizer-BioNTech and Moderna's mRNA vaccines must be kept at extremely low temperatures during storage, which is difficult in low- and middle-income nations. According to Gennova, mRNA is not contagious, does not integrate, and is broken down by normal cellular processes, making mRNA vaccines safe. Because of its technology, the vaccine may be quickly modified to account for any new or emerging viral strains.

Reference: -